Viewing data from:

TERIFLUNOMIDE

ANDA

TERIFLUNOMIDE | A209549 | WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC

2 strengths0 unique patents0 unique exclusivities

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
Sanofi-Aventis U.S. LLC et al v. Cadila Healthcare Limited et al 1:2016cv01298 2 patentsANDA 209549teriflunomide	D. Del.	2016-12-22	Terminated 2018-01-02	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Medicare Part D Spending

CMS annual spending data for Teriflunomide (2023)

Total Spending

$110.4M

Total Claims

29,686

Beneficiaries

5,394

Avg Cost/Unit

$105.92

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain20 active DMFs

20 active API suppliers hold Drug Master Files for this ingredient.

MSN LABORATORIES PRIVATE LTDTERIFLUNOMIDE [ROUTE CODE "TO"]

DMF 278602014

ALEMBIC PHARMACEUTICALS LTDTERIFLUNOMIDE

DMF 288982016

ALIVUS LIFE SCIENCES LTDTERIFLUNOMIDE

DMF 289912015

HONOUR LAB LTDTERIFLUNOMIDE

DMF 297012015

UNICHEM LABORATORIES LTDTERIFLUNOMIDE

DMF 297052015

MEGAFINE PHARMA P LTDTERIFLUNOMIDE DRUG SUBSTANCE

DMF 298022015

RAKS PHARMA PVT LTDTERIFLUNOMIDE

DMF 298512015

FORMOSA LABORATORIES INCTERIFLUNOMIDE

DMF 298622015

PHARMAZELL GMBHTERIFLUNOMIDE

DMF 302202016

BIOCON LTDTERIFLUNOMIDE

DMF 302972016

APITORIA PHARMA PRIVATE LTDTERIFLUNOMIDE

DMF 303402016

OLON SPATERIFLUNOMIDE

DMF 303462016

EMCURE PHARMACEUTICALS LTDTERIFLUNOMIDE

DMF 304142016

ZYDUS LIFESCIENCES LTDTERIFLUNOMIDE

DMF 304262016

INTAS PHARMACEUTICALS LTDTERIFLUNOMIDE

DMF 304912016

NATCO PHARMA LTDTERIFLUNOMIDE

DMF 305062016

TIANJIN WEIJIE PHARMACEUTICAL CO LTDTERIFLUNOMIDE

DMF 309782016

SHILPA PHARMA LIFESCIENCES LTDTERIFLUNOMIDE

DMF 321722017

MAPRIMED SATERIFLUNOMIDE

DMF 366222021

OPTIMUS DRUGS PRIVATE LTDTERIFLUNOMIDE

DMF 366532021

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Aug 17, 2018	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — 7MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Jul 27, 2018

No patent or exclusivity listings for this strength.

#002 — 14MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jul 27, 2018